Evidence map›Paper›PMID 31208049›Full record

ArticleCells2019

Melanin and Neuromelanin Fluorescence Studies Focusing on Parkinson's Disease and Its Inherent Risk for Melanoma.

Dieter Leupold, Lukasz Szyc, Goran Stankovic, Sabrina Strobel, Hans-Ullrich Völker, Ulrike Fleck, Thomas Müller, Matthias Scholz, Peter Riederer, Camelia-Maria Monoranu

Open access · goldAbstract read
In one paragraph

Article in Cells, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed, 1 pooled it
0.6field-weighted citation impact, top 37% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 1 synthesis or guideline pooled it, 12 citations in OpenAlex.

  1. Pooled it
  2. In Vivo UV-Induced Fluorescence Spectroscopy of Skin in Parkinson's Disease.Doklady biological sciences : proceedings of the Academy of Sciences of the USSR, Biological sciences sections · 2025
    Article
  3. Article
  4. Article
  5. Article
  6. Neuromelanin in Parkinson's Disease: Tyrosine Hydroxylase and Tyrosinase.International journal of molecular sciences · 2022
    Review
  7. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 5 institutions in 2 countries.

Dieter LeupoldLTB Lasertechnik Berlin GmbH, 12489 Berlin, Germany. dieter.leupold@ltb-berlin.de.
Lukasz SzycMagnosco GmbH, 12489 Berlin, Germany. lukasz.szyc@magnosco.com.ORCID 0000-0001-5102-7383
Goran StankovicMagnosco GmbH, 12489 Berlin, Germany. goran.stankovic@magnosco.com.
Sabrina StrobelInstitute of Pathology, Department of Neuropathology, University of Wuerzburg, Comprehensive Cancer Center (CCC) Mainfranken Wuerzburg, 97080 Wuerzburg, Germany. sabrina.strobel@uni-wuerzburg.de.
Hans-Ullrich VölkerPathology, Leopoldina Krankenhaus GmbH, Gustav-Adolf-Str 8, D-97422 Schweinfurt, Germany. hvoelker@leopoldina.de.
Ulrike FleckDermatology Practice, 10117 Berlin, Germany. kontakt@hautarzt-fleck.de.
Thomas MüllerDepartment of Neurology, St. Joseph Hospital Berlin-Weißensee, 13088 Berlin, Germany. Th.Mueller@alexianer.de.
Matthias ScholzLTB Lasertechnik Berlin GmbH, 12489 Berlin, Germany. matthias.scholz@ltb-holding.de.
Peter RiedererCenter of Mental Health, Department of Psychiatry, Psychosomatics and Psychotherapy, Margarete-Hoeppel-Platz 1, 97080 Wuerzburg, Germany. peter.riederer@mail.uni-wuerzburg.de.
Camelia-Maria MonoranuInstitute of Pathology, Department of Neuropathology, University of Wuerzburg, Comprehensive Cancer Center (CCC) Mainfranken Wuerzburg, 97080 Wuerzburg, Germany. camelia-maria.monoranu@uni-wuerzburg.de.
Comprehensive Cancer Center Mainfranken · DELaser- und Medizin-Technologie (Germany) · DELeopoldina Krankenhaus Schweinfurt · DESt. Joseph-Krankenhaus · DEUniversity of Southern Denmark · DK

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Parkinson's disease is associated with an increased risk of melanoma (and vice versa). Several hypotheses underline this link, such as pathways affecting both melanin and neuromelanin. For the first time, the fluorescence of melanin and neuromelanin is selectively accessible using a new method of nonlinear spectroscopy, based on a stepwise two-photon excitation. Cutaneous pigmentation and postmortem neuromelanin of Parkinson patients were characterized by fluorescence spectra and compared with controls. Spectral differences could not be documented, implying that there is neither a Parkinson fingerprint in cutaneous melanin spectra nor a melanin-associated fingerprint indicating an increased melanoma risk. Our measurements suggest that Parkinson's disease occurs without a configuration change of neuromelanin. However, Parkinson patients displayed the same dermatofluorescence spectroscopic fingerprint of a local malignant transformation as controls. This is the first comparative retrospective fluorescence analysis of cutaneous melanin and postmortem neuromelanin based on nonlinear spectroscopy in patients with Parkinson's disease and controls, and this method is a very suitable diagnostic tool for melanoma screening and early detection in Parkinson patients. Our results suggest a non-pigmentary pathway as the main link between Parkinson's disease and melanoma, and they do not rule out the melanocortin-1-receptor gene as an additional bridge between both diseases.

Indexed as

AdultAgedAged, 80 and overAnimalsBrainCase-Control StudiesFemaleFluorescenceHumansMaleMelaninsMelanomaMiddle AgedParkinson DiseasePostmortem ChangesRisk FactorsMelaninsneuromelanindermatofluoroscopymelaninneuromelaninParkinson’s disease

Identifiers

PMID31208049
PMCPMC6627191
OpenAlexW2953002049

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.